* Cell Genesys Inc., of Foster City, Calif., reported thatits researchers engineered novel adenoviral vectors thatare capable of long-term gene expression and can avoidtoxicities associated with earlier versions of the vectors.The work will broaden the company's gene therapyprogram for cancer by allowing in vivo administration ofgenes.
* CoCensys Inc., of Irvine, Calif., completed a Phase Itrial that showed ACEA 1021, a glycine-site N-Methyl-D-Aspartate receptor antagonist for stroke, was welltolerated and had no side effects.
* Neurex Corp., of Menlo Park, Calif., said a Phase I/IIstudy of SNX-111 for severe pain in seven patientsshowed the agent has potential to provide symptomaticrelief in those who had failed other pain therapy, withoutthe side effects seen with opiates. Neurex intends to startcontrolled studies by the end of the year.
(c) 1997 American Health Consultants. All rights reserved.